PHARVARIS NV (PHVS) Stock Analyst Ratings
USA - NASDAQ:PHVS - NL00150005Y4 - Common Stock
23.55 USD
-0.71 (-2.93%)
ChartMill assigns a Buy % Consensus number of 87% to PHVS. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 37.31. This target is 58.45% above the current price.
PHVS was analyzed by 18 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about PHVS.
In the previous month the buy percentage consensus was at a similar level.
PHVS was analyzed by 18 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-11-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-11-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-10-15 | HC Wainwright & Co. | Initiate | Buy |
| 2025-10-09 | B of A Securities | Upgrade | Underperform -> Neutral |
| 2025-08-13 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2025-06-05 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-05-14 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-03-03 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-01-31 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-09-19 | Jones Trading | Initiate | Buy |
| 2024-09-06 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-07-03 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-05-09 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-04-22 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-04-15 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2024-04-11 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2024-04-11 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-03-19 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-02-14 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2024-01-23 | JMP Securities | Maintains | Market Outperform -> Market Outperform |
| 2023-12-07 | B of A Securities | Maintains | Underperform -> Underperform |
| 2023-12-07 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-11-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-11-03 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-09-25 | Wedbush | Initiate | Outperform |
| 2023-08-15 | Morgan Stanley | Upgrade | Equal-Weight -> Overweight |
| 2023-08-01 | Morgan Stanley | Reiterate | Equal-Weight -> Equal-Weight |
| 2023-07-31 | Morgan Stanley | Reiterate | Equal-Weight -> Equal-Weight |
PHARVARIS NV / PHVS FAQ
What do analysts expect the price target to be for PHARVARIS NV (PHVS)?
18 analysts have analysed PHVS and the average price target is 37.32 USD. This implies a price increase of 58.45% is expected in the next year compared to the current price of 23.55.
How do analysts rate PHARVARIS NV (PHVS)?
The consensus rating for PHARVARIS NV (PHVS) is 86.6667 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for PHARVARIS NV stock?
The number of analysts covering PHARVARIS NV (PHVS) is 18.